JP2017500017A - 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 - Google Patents

生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Download PDF

Info

Publication number
JP2017500017A
JP2017500017A JP2016532136A JP2016532136A JP2017500017A JP 2017500017 A JP2017500017 A JP 2017500017A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A JP2017500017 A JP 2017500017A
Authority
JP
Japan
Prior art keywords
culture
cells
cell
liters
cumulative amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500017A5 (cg-RX-API-DMAC7.html
Inventor
ウィリアム シー． ヤン，
ウィリアム シー． ヤン，
ジウイー ル，
ジウイー ル，
ヤオ−ミン フアン，
ヤオ−ミン フアン，
ハン ユアン，
ハン ユアン，
ラシュミ クシルサガル，
ラシュミ クシルサガル，
トーマス リル，
トーマス リル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2017500017A publication Critical patent/JP2017500017A/ja
Publication of JP2017500017A5 publication Critical patent/JP2017500017A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016532136A 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Withdrawn JP2017500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919629P 2013-12-20 2013-12-20
US61/919,629 2013-12-20
PCT/US2014/071701 WO2015095809A1 (en) 2013-12-20 2014-12-19 Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000268A Division JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Publications (2)

Publication Number Publication Date
JP2017500017A true JP2017500017A (ja) 2017-01-05
JP2017500017A5 JP2017500017A5 (cg-RX-API-DMAC7.html) 2018-02-08

Family

ID=52347449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016532136A Withdrawn JP2017500017A (ja) 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Country Status (4)

Country Link
US (2) US20160289633A1 (cg-RX-API-DMAC7.html)
EP (1) EP3083933A1 (cg-RX-API-DMAC7.html)
JP (3) JP2017500017A (cg-RX-API-DMAC7.html)
WO (1) WO2015095809A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US20180312802A1 (en) * 2015-11-02 2018-11-01 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins in perfusion mode
KR102739324B1 (ko) 2016-01-26 2024-12-09 베링거 인겔하임 인터내셔날 게엠베하 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템
EP3504315A4 (en) 2016-08-27 2020-04-15 3D Biotek, LLC BIOREACTOR
CN111344558A (zh) 2017-10-06 2020-06-26 龙沙有限公司 使用拉曼光谱法自动控制细胞培养
EA202090740A1 (ru) 2017-10-16 2020-07-07 Ридженерон Фармасьютикалз, Инк. Перфузионный биореактор и связанные с ним способы применения
WO2019094333A1 (en) * 2017-11-13 2019-05-16 Amgen Inc. Methods for producing protein products
KR20250111232A (ko) * 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
CA3098565A1 (en) * 2018-04-29 2019-11-07 Claire G. ZHANG Scalable clarification process for recombinant aav production
US12071607B2 (en) * 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP7453151B2 (ja) * 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
AU2020212042A1 (en) * 2019-01-25 2021-08-26 Biogen Ma Inc. Seed culture process for AAV production
KR20220039777A (ko) * 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
TW202309087A (zh) * 2021-05-03 2023-03-01 德商百靈佳殷格翰國際股份有限公司 製備spesolimab之方法
US20230279433A1 (en) 2021-12-15 2023-09-07 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
CA3245327A1 (en) * 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. MODIFIED BATCH-BASED AAV PRODUCTION SYSTEMS AND PROCESSES
WO2024054414A1 (en) * 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
EP1395647B1 (en) * 2000-12-20 2006-11-22 Bayer Pharmaceuticals Corporation A device and method for seed-train expansion of mammalian cells
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
JPWO2003071271A1 (ja) 2002-02-21 2005-06-16 東京瓦斯株式会社 医薬品の薬理作用を評価するための検査薬、並びに酵素、酵素阻害剤若しくは受容体リガンドからなる薬物および／またはそのプロドラッグの中から投与効果が高いものおよび／または副作用が小さいものをスクリーニングする方法および試薬
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1720972B1 (en) * 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
MX345141B (es) * 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
CN102083856A (zh) 2008-04-16 2011-06-01 拜耳医药保健有限公司 经修饰的因子ix多肽及其用途
KR20110015551A (ko) 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
WO2009129814A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
UA106047C2 (uk) * 2008-06-13 2014-07-25 Сентокор Орто Байотек Інк. Спосіб отримання високої щільності життєздатних клітин в культурі клітин ссавців
KR101770849B1 (ko) 2009-12-06 2017-09-05 바이오버라티브 테라퓨틱스 인크. 인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
EP2529006A4 (en) * 2010-01-25 2014-01-08 Ventria Bioscience METHODS AND COMPOSITIONS FOR IMPROVING PROTEIN PRODUCTION
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
CN103415610B (zh) 2011-03-18 2016-10-19 通用电气健康护理生物科学股份公司 用于培养细胞的弹性袋
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PADAWER ISHAI ET AL.: "Case Study: An accelerated 8-day monoclonal antibody production process based on high seeding densit", BIOTECHNOLOGY PROGRESS, vol. 29, no. 3, JPN6018041861, 18 April 2013 (2013-04-18), pages 829 - 832, ISSN: 0004230568 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP7684224B2 (ja) 2019-04-11 2025-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP7680418B2 (ja) 2019-07-16 2025-05-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造

Also Published As

Publication number Publication date
JP2020054388A (ja) 2020-04-09
US20250382568A1 (en) 2025-12-18
EP3083933A1 (en) 2016-10-26
JP2023022317A (ja) 2023-02-14
WO2015095809A1 (en) 2015-06-25
US20160289633A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
US20250382568A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fedbatch production capacity and product quality
US20230117598A1 (en) Mammalian cell culture
KR101540124B1 (ko) 항노화 화합물을 사용하는 단백질의 생산 방법
KR102604988B1 (ko) 관류 배지
KR102604992B1 (ko) 관류 배지
US10676772B2 (en) Control of protein glycosylation by culture medium supplementation and cell culture process parameters
JP2024050574A (ja) 哺乳動物細胞培養物によって生産されるニューブラスチン抗体
US20150353883A1 (en) Medium Supplements for Improved Process Performance
JP7495483B2 (ja) 濃縮灌流培地
US12441980B2 (en) Methods for overcoming glutamine deprivation during mammalian cell culture
US10717965B2 (en) Mammalian cell culture-produced neublastin antibodies
JP2021503916A (ja) 哺乳動物細胞の培養方法
US20170029859A1 (en) Medium supplements for improved process performance
US20170327786A1 (en) Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
HK1142095B (en) Methods of protein production using anti-senescence compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200319